Medical case reports of Candidozyma auris (syn. Candida auris) infections in Europe - a systematic review
DOI:
https://doi.org/10.17420/ap71.560Keywords:
Candida, Candidozyma auris, systematic review, case studyAbstract
Purpose: Candidozyma auris (syn. Candida auris) is a hazardous multi-drug resistant yeast that causes severe infections in hospitalized patients. Many uncertainties exist around its antifungal resistance, clinical presentation, dominant clade, and isolation sites in the European setting. Therefore, to properly assess these characteristics, we systematically reviewed case reports in Europe between the first case described in 2009 and November 2024.
Methods: We conducted this systematic review according to the PRISMA guidelines. Cases of both symptomatic and asymptomatic patients have been included. We extracted patients’ demographics, C. auris isolation site, identified clade, clinical presentation, clinical outcome, as well as treatment. The case reports have been assessed for quality using standardized tools.
Results: Out of 251 identified articles, 12 reports from 10 European countries describing 15 cases are included In the review. The youngest affected person was an infant and the oldest was 74 years old. Blood was the most common isolation site, reported in 26% of reported cases. The fatality rate could not have been reported due to the high number of asymptomatic patients and comorbidities or other infections in symptomatic patients. About 91% of reported isolates were resistant to fluconazole, 18% to amphotericin B and none was resistant to echinocandins. The quality assessment revealed that about 33% of case reports had a high risk of bias.
Conclusions: Our results show that any age group can be affected. The antimicrobials of choice in the European setting seem to be the echinocandins, although proper standardized susceptibility breakpoints are needed.
References
[1] Liu F., Hu Z.D., Zhao X.M., Zhao W.N., Feng Z.X., Yurkov A. et al. 2024. Phylogenomic analysis of the Candida auris–Candida haemuli clade and related taxa in the Metschnikowiaceae, and proposal of thirteen new genera, fifty-five new combinations and nine new species. Persoonia 52: 22–43. https://doi.org/10.3767/persoonia.2024.52.02
[2] Satoh K., Makimura K., Hasumi Y., Nishiyama Y., Uchida K., Yamaguchi H. 2009. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiology and Immunology 53(1): 41–44. https://doi.org/10.1111/j.1348-0421.2008.00083.x
[3] Lee W.G., Shin J.H., Uh Y., Kang M.G., Kim S.H., Park K.H. et al. 2011. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 49(9): 3139–42. https://doi.org/10.1128/JCM.00319-11
[4] Ahmad S., Alfouzan W. 2021. Candida auris: epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. Micro-organisms 9(4). https://doi.org/10.3390/microorganisms9040807
[5] Desoubeaux G., Coste A.T., Imbert C., Hennequin C. 2022. Overview about Candida auris: What's up 12 years after its first description? J Mycol Med. 32(2): 101248. https://doi.org/10.1016/j.mycmed.2022.101248
[6] Al Maani A., Paul H., Al-Rashdi A., Al Wahaibi A., Al-Jardani A., Al Abri A.M.A. et al. 2019. Ongoing challenges with healthcare-associated Candida auris outbreaks in Oman. Journal of Fungi 5(4). https://doi.org/ 10.3390/jof5040101
[7] Garcia C.S., Palop N.T., Bayona J.V.M., Garcia M.M., Rodriguez D.N., Alvarez M.B. et al. 2020. Candida auris: report of an outbreak. Enfermedades Infecciosas Y Microbiologia Clinica 38: 39–44. https://doi.org/10.1016/j.eimc.2020.02.007
[8] Biran R., Cohen R., Finn T., Brosh-Nissimov T., Rahav G., Yahav D. et al. 2023. Nationwide outbreak of Candida auris infections driven by COVID-19 hospitalizations, Israel, 2021–2022. Emerg Infect Dis. 29(7):1297–1301. https://doi.org/10.3201/eid2907.221888
[9] WHO. 2022. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization. Available from: https://www.who.int/publications/i/ item/9789240060241
[10] Bidaud AL, Chowdhary A, Dannaoui E.2018. Candida auris: An emerging drug resistant yeast – A mini-review. J Mycol Med. 28(3): 568–573. https://doi.org/10.1016/j.mycmed.2018.06.007
[11] Spivak E.S., Hanson K.E. 2018. Candida auris: an Emerging Fungal Pathogen. J Clin Microbiol. 56(2): e01588-17. https://doi.org/10.1128/JCM.01588-17
[12] Casadevall A., Kontoyiannis D.P., Robert V. 2019. On the emergence of Candida auris: Climate change, azoles, swamps, and birds. mBio 10(4): e01397-19. https://doi.org/10.1128/mBio.01397-19
[13] Jensen R.H. 2016. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment. Dan Med J. 63(10): B5288.
[14] de Jong A.W., Hagen F. 2019. Attack, defend and persist: How the fungal pathogen Candida auris was able to emerge globally in healthcare environments. Mycopathologia 184(3): 353–365. https://doi.org/10.1007/s11046-019-00351-w
[15] Bravo Ruiz G, Lorenz A. 2021. What do we know about the biology of the emerging fungal pathogen of humans Candida auris? Microbiol Res. 242: 126621. https://doi.org/10.1016/j.micres.2020.126621
[16] Borman A.M, Szekely A., Johnson E.M. 2016. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere. 1(4): e00189-16. https://doi.org/10.1128/mSphere.00189-16
[17] Chakrabarti A., Singh S. 2020. Multidrug-resistant Candida auris: an epidemiological review. Expert review of anti-infective therapy 18(6): 551–562. https://doi.org/10.1080/14787210.2020.1750368
[18] Kean R, Ramage G. 2019. Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris. mSphere. 2019;4(4): e00458-19. https://doi.org/10.1128/mSphere.00458-19
[19] Rybak J.M., Muñoz J.F., Barker K.S., Parker J.E., Esquivel B.D., Berkow E.L. et al. 2020. Mutations in TAC1B: a novel genetic determinant of clinical fluconazole resistance in Candida auris. mBio 11(3): e00365-20. https://doi.org/10.1128/mBio.00365-20
[20] Fasciana T., Cortegiani A., Ippolito M., Giarratano A., Di Quattro O., Lipari D. et al. 2020. Candida auris: An overview of how to screen, detect, test and control this emerging pathogen. Antibiotics (Basel) 9(11): 778. https://doi.org/10.3390/antibiotics9110778
[21] Chybowska A.D., Childers D.S., Farrer R.A. 2020. Nine things genomics can tell us about Candida auris. Front Genet. 11: 351. https://doi.org/10.3389/fgene.2020.00351
[22] Sears D, Schwartz B.S. 2017. Candida auris: An emerging multidrug-resistant pathogen. Int J Infect Dis. 63:95-98. https://doi.org/10.1016/j.ijid.2017.08.017
[23] Sarma S., Upadhyay S. 2017. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 10: 155–165. https://doi.org/10.2147/IDR.S116229
[24] Hoenigl M., Seidel D., Sprute R., Cunha C., Oliverio M., Goldman G.H. et al. 2022. COVID-19-associated fungal infections. Nat Microbiol. 7(8): 1127–1140. https://doi.org/10.1038/s41564-022-01172-2
[25] Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D. et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372: n71. https://doi.org/10.1136/bmj.n71
[26] CDC. Candida auris: Antifungal Susceptibility Testing and Interpretation. Available from: https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html (accessed on 21 February 2023)
[27] Moola S., Munn Z., Tufanaru C., Aromataris E., Sears K., Sfetcu R. et al. 2020. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E., Munn Z. (Editors). JBI Manual for Evidence Synthesis: JBI https://doi.org/10.46658/JBIMES-20-08
[28] Mesini A., Saffioti C., Mariani M., Florio A., Medici C., Moscatelli A. et al. 2021. First case of Candida auris colonization in a preterm, extremely low-birth-weight newborn after vaginal delivery. J Fungi (Basel) 7(8): 649. https://doi.org/10.3390/jof7080649
[29] Riat A., Neofytos D., Coste A., Harbarth S., Bizzini A., Grandbastien B. et al. 2018. First case of Candida auris in Switzerland: discussion about preventive strategies. Swiss Med Wkly 148: w14622. https://doi.org/10.4414/smw.2018.14622
[30] Theut M., Antsupova V., Andreasen A.S., Buhl D., Midttun M., Knudsen J.D. et al. 2022. The first two cases of Candida auris in Denmark. Ugeskrift for laeger 184(16): V10210768.
[31] Crea F., Codda G., Orsi A., Battaglini A., Giacobbe D.R., Delfino E. et al. 2019. Isolation of Candida auris from invasive and non-invasive samples of a patient suffering from vascular disease, Italy, July 2019. Euro Surveill. 24(37). https://doi.org/10.2807/1560-7917.ES.2019.24.37.1900549
[32] Stathi A., Loukou I., Kirikou H., Petrocheilou A., Moustaki M., Velegraki A. et al. 2019. Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019. Euro Surveill. 24(29): 1900400. https://doi.org/ 10.2807/1560-7917.ES.2019.24.29.1900400.
[33] Steinmann J., Schrauzer T., Kirchhoff L., Meis J.F., Rath P.M. 2021. Two Candida auris cases in Germany with no recent contact to foreign healthcare-epidemiological and microbiological investigations. J Fungi (Basel) 7(5): 380. https://doi.org/10.3390/jof7050380
[34] Vogelzang E.H., Weersink A.J.L., van Mansfeld R., Chow N.A., Meis J.F., van Dijk K. 2019. The first two cases of Candida auris in the Netherlands. J Fungi (Basel) 5(4): 91. https://doi.org/10.3390/jof5040091
[35] Prazynska M., Zalas-Wiecek P., Bogiel T., Wlodarczyk Z., Deptula A., Wozniak M. et al. 2023. Candida auris infection in a meningococcal septicemia survivor, Poland. Mycopathologia 188(1–2): 135–141. https://doi.org/10.1007/s11046-022-00697-8
[36] Reque J., Arlandis R., Panizo N., Pascual M.J., Perez-Alba A. 2022. Candida auris Invasive Infection after Kidney Transplantation. Case Rep Nephrol. 2022: 6007607. https://doi.org/10.1155/2022/6007607
[37] Pekard-Amenitsch S., Schriebl A., Posawetz W., Willinger B., Kölli B., Buzina W. 2018. Isolation of Candida auris from ear of otherwise healthy patient, Austria, 2018. Emerg Infect Dis. 24(8): 1596–1597. https://doi.org/10.3201/eid2408.180495
[38] Rimoldi S.G., Nodari R., Rizzo A., Tamoni A., Longobardi C., Pagani C., et al. 2024. First imported case of Candida auris infection in Milan, Italy: genomic characterisation. Infection, 52(4), 1633–1638. https://doi.org/10.1007/s15010-024-02232-x
[39] Henriques J., Mixão V., Cabrita J., Duarte T.I., Sequeira T., Cardoso S. et al. 2023. Candida auris in intensive care setting: the first case reported in Portugal. J Fungi (Basel) 9(8): 837. https://doi.org/10.3390/jof9080837
[40] Caceres D.H., Forsberg K., Welsh R.M., Sexton D.J., Lockhart S.R., Jackson B.R. et al. 2019. Candida auris: A review of recommendations for detection and control in healthcare settings. J Fungi (Basel) 5(4): 111. https://doi.org/10.3390/jof5040111
[41] Osei Sekyere J. 2018. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen 7(4): e00578. https://doi.org/10.1002/mbo3.578
[42] Geremia N., Brugnaro P., Solinas M., Scarparo C., Panese S. 2023. Candida auris as an emergent public health problem: a current update on european outbreaks and cases. Healthcare (Basel) 11(3): 425. https://doi.org/10.3390/healthcare11030425
[43] Kohlenberg A., Monnet D.L., Plachouras D. 2022. Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. Euro Surveill. 27(46): 2200846. https://doi.org/10.2807/1560-7917.ES.2022.27.46.2200846
[44] European Centre for Disease Prevention and control Candida auris in healthcare settings – Europe. Available from: https://www.ecdc.europa.eu/sites/ default/files/documents/RRA-Candida-auris-European- Union-countries-first-update.pdf (accessed on 16 February 2023)
[45] Ahmad S., Asadzadeh M. 2023. Strategies to prevent transmission of Candida auris in healthcare settings. Curr Fungal Infect Rep. 17(1): 36–48. https://doi.org/10.1007/s12281-023-00451-7
[46] Garcia-Bustos V., Cabanero-Navalon M.D, Ruiz-Saurí A., Ruiz-Gaitán A.C., Salavert M., Tormo M. et al. 2021. What do we know about Candida auris? State of the art, knowledge gaps, and future directions. Microorganisms 9(10): 2177. https://doi.org/10.3390/microorganisms9102177
[47] Schelenz S., Hagen F., Rhodes J.L., Abdolrasouli A., Chowdhary A., Hall A. et al. 2016. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrobial Resistance and Infection Control 5: 35. https://doi.org/10.1186/s13756-016-0132-5
[48] Kullberg B.J., Arendrup M.C. 2015. Invasive candidiasis. N Engl J Med. 373(15): 1445–1456. https://doi.org/ 10.1056/NEJMra1315399
[49] Jamalian A., Freeke J., Chowdhary A., de Hoog G.S., Stielow J.B., Meis J.F. 2023. Fast and accurate identification of Candida auris by High Resolution Mass Spectrometry. J Fungi (Basel) 9(2): 267. https://doi.org/10.3390/jof9020267
[50] Cornely O.A, Bassetti M., Calandra T., Garbino J., Kullberg B.J., Lortholary O. et al. 2012. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 18(Suppl 7): 19–37. https://doi.org/10.1111/1469-0691.12039
[51] Cortegiani A., Misseri G., Fasciana T., Giammanco A., Giarratano A., Chowdhary A. 2018. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care 6: 69. https://doi.org/10.1186/s40560-018-0342-4
[52] Navalkele B.D., Revankar S., Chandrasekar P. 2017. Candida auris: a worrisome, globally emerging pathogen. Expert Rev Anti Infect Ther. 15(9): 819–827. https://doi.org/10.1080/14787210.2017.1364992
[53] Aslam S., Rotstein C. 2019. Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 33(9): e13623. https://doi.org/10.1111/ctr.13623
[54] Heath C.H., Dyer J.R., Pang S., Coombs G.W., Gardam D.J. 2015. Candida auris Sternal Osteomyelitis in a Man from Kenya Visiting Australia, 2015. Emerg Infect Dis. 25(1): 192–194. https://doi.org/10.3201/eid2501.181321
[55] Centers for Disease Control and Prevention Candida auris Screening. Available from: https://www.cdc.gov/fungal/candida-auris/c-auris-screening.html (accessed on 16 February 2023)
[56] Chakrabarti A., Sood P. 2021. On the emergence, spread and resistance of Candida auris: host, pathogen and environmental tipping points. J Med Microbiol. 70(3): 001318. https://doi.org/10.1099/jmm.0.001318
[57] Gómez-Gaviria M., Martínez-Álvarez J.A., Chávez-Santiago J.O., Mora-Montes H.M. 2023. Candida haemulonii complex and Candida auris: biology, virulence factors, immune response, and multidrug resistance. Infect Drug Resist. 16: 1455-1470. https://doi.org/10.2147/IDR.S402754
[58] Ninan M.M., Sahni R.D., Chacko B., Balaji V., Michael J.S. 2020. Candida auris: Clinical profile, diagnostic challenge and susceptibility pattern: Experience from a tertiary-care centre in South India. Journal of Global Antimicrobial Resistance 21: 181–185. https://doi.org/10.1016/j.jgar.2019.10.018
[59] Di Pilato V., Codda G., Ball L., Giacobbe D.R., Willison E, Mikulska M, et al. 2021. Molecular epidemiological investigation of a nosocomial cluster of C. auris: evidence of recent emergence in Italy and ease of transmission during the COVID-19 Pandemic. Journal of Fungi 7(2): 140. https://doi.org/10.3390/jof7020140
[60] Candida auris outbreak in healthcare facilities in northern Italy, 2019–2021. Available from: https://www.ecdc.europa.eu/sites/ default/files/documents/RRA-candida-auris-Feb2022.pdf (accessed on 10 October 2023)
[61] Treatment and Management of C. auris Infections and Colonization. Available from: https://www.cdc.gov/fungal/candida-auris/c-auris-treatment.html (accessed on 10 October 2023)
[62] Ghannoum M., Arendrup M.C., Chaturvedi V.P., Lockhart S.R., McCormick T.S., Chaturvedi S. et al. 2020. Ibrexafungerp: A novel oral triterpenoid antifungal in development for the treatment of Candida auris infections. Antibiotics (Basel) 9(9): 539. https://doi.org/10.3390/antibiotics9090539
[63] Sahu R.K., Yadav R., Prasad P., Roy A., Chandrakar S. 2014. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. Springerplus 3: 695.
[64] Warris A. 2018. Candida auris, what do paediatricians need to know? Arch Dis Child. 103(9): 891–894. https://doi.org/10.1186/2193-1801-3-695
